EPIX ESSA Pharma Inc. Stock Quote

EPIX [NASD]

Index	-	P/E	-	EPS (ttm)	-0.86	Insider Own	11.30%	Shs Outstand	44.03M	Perf Week	-3.51%
Market Cap	239.42M	Forward P/E	-	EPS next Y	-1.37	Insider Trans	-0.51%	Shs Float	41.15M	Perf Month	-6.46%
Income	-37.30M	PEG	-	EPS next Q	-0.28	Inst Own	86.10%	Short Float	6.09%	Perf Quarter	-32.68%
Sales	-	P/S	-	EPS this Y	8.40%	Inst Trans	-0.32%	Short Ratio	9.86	Perf Half Y	-60.20%
Book/sh	4.06	P/B	1.35	EPS next Y	-30.10%	ROA	-19.20%	Target Price	31.40	Perf Year	-82.61%
Cash/sh	4.16	P/C	1.32	EPS next 5Y	-	ROE	-19.60%	52W Range	5.22 - 33.84	Perf YTD	-61.27%
Dividend	-	P/FCF	-	EPS past 5Y	37.20%	ROI	-	52W High	-83.75%	Beta	1.54
Dividend %	-	Quick Ratio	48.60	Sales past 5Y	-	Gross Margin	-	52W Low	5.47%	ATR	0.49
Employees	30	Current Ratio	48.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	40.65	Volatility	7.10% 9.06%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	30.60%	Profit Margin	-	Rel Volume	1.02	Prev Close	5.30
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	254.06K	Price	5.50
Recom	-	SMA20	-4.49%	SMA50	-12.59%	SMA200	-39.58%	Volume	259,699	Change	3.77%

Mar-04-21

Initiated

Piper Sandler

Overweight

$50

Jan-11-21

Reiterated

H.C. Wainwright

Buy

$10 → $17

Nov-02-20

Initiated

Jefferies

Buy

$17

Oct-25-19

Initiated

Oppenheimer

Outperform

May-27-22 08:12AM	EPIX: Clinical Update on Phase 1 Monotherapy Trial of EPI-7386 Expected in 2Q22 Zacks Small Cap Research
May-10-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022 CNW Group +7.68%
Apr-26-22 04:30PM	ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference PR Newswire
04:30PM	ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference CNW Group
Apr-25-22 10:20AM	EPIX: Preclinical Data on Androgen Receptor N-Terminal Domain Degrader Presented at AACR Zacks Small Cap Research
Apr-08-22 01:00PM	ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders CNW Group
Mar-10-22 04:05PM	ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference CNW Group
Mar-09-22 11:34PM	ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS PR Newswire
11:34PM	ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS CNW Group
Mar-08-22 04:30PM	ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting PR Newswire
04:30PM	ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting CNW Group
Feb-04-22 05:16AM	EPIX: First Patient Dosed in Combination Trial of EPI-7386 and Enzalutamide Zacks Small Cap Research +5.13%
Feb-03-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021 PR Newswire
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021 CNW Group
Jan-19-22 07:00AM	ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer PR Newswire
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com
Dec-21-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com
Dec-16-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com -6.80%
Dec-11-21 05:38AM	Penn Series Small Cap Growth Fund Buys Core & Main Inc, Clear Secure Inc, Inotiv Inc, Sells ... GuruFocus.com
Dec-08-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com
Nov-22-21 09:20AM	EPIX: Combination Studies Set to Initiate Zacks Small Cap Research
Nov-18-21 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021 CNW Group
Nov-08-21 07:00AM	ESSA Pharma to Participate in Three Upcoming Investor Conferences PR Newswire
07:00AM	ESSA Pharma to Participate in Three Upcoming Investor Conferences CNW Group
Oct-28-21 04:05PM	ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat PR Newswire
04:05PM	ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat CNW Group
Oct-19-21 01:21PM	Hedge Funds Are Done Buying ESSA Pharma Inc. (EPIX) Insider Monkey +5.13%
Oct-07-21 10:25AM	ESSA Pharma, Caris Life Sciences Ink Liquid Biopsy Profiling Pact Benzinga +5.03%
09:00AM	ESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386 CNW Group
06:30AM	Caris Life Sciences and ESSA Pharma Announce Liquid Biopsy Profiling Collaboration PR Newswire
Aug-31-21 04:05PM	ESSA Pharma to Present at Upcoming September Investor Conferences PR Newswire
04:05PM	ESSA Pharma to Present at Upcoming September Investor Conferences CNW Group
Aug-24-21 06:30AM	EPIX: Unwarranted Selloff Following Phase 1 Trial Update Zacks Small Cap Research +6.93%
04:30AM	EPIX: Unwarranted Selloff Following Phase 1 Trial Update Zacks Small Cap Research
Aug-16-21 02:32PM	Mid-Afternoon Market Update: Dow Turns Positive; Sesen Bio Shares Plummet Benzinga -34.48%
12:13PM	Mid-Day Market Update: Crude Oil Down Over 2%; Travere Therapeutics Shares Jump Benzinga
10:22AM	Mid-Morning Market Update: Markets Open Lower; Empire State Manufacturing Index Dips In August Benzinga
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2021 PR Newswire
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2021 CNW Group
Jul-13-21 12:38PM	Hedge Funds Are Crazy About ESSA Pharma Inc. (EPIX) Insider Monkey
May-25-21 07:00AM	ESSA Pharma to Present at the Jefferies Virtual Healthcare Conference PR Newswire
May-10-21 10:59AM	EPIX: Combination Trials Upcoming with Astellas, Bayer, and Janssen Zacks Small Cap Research
May-06-21 07:01AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021 PR Newswire
07:01AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021 CNW Group
Apr-28-21 07:00AM	ESSA Pharma Announces Clinical Collaboration Agreement with Bayer to Evaluate the Combination of EPI-7386 and Darolutamide in Patients with Metastatic Castration-Resistant Prostate Cancer PR Newswire +7.20%
07:00AM	ESSA Pharma Announces Clinical Collaboration Agreement with Bayer to Evaluate the Combination of EPI-7386 and Darolutamide in Patients with Metastatic Castration-Resistant Prostate Cancer CNW Group
Apr-14-21 07:00AM	ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference PR Newswire
07:00AM	ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference CNW Group
Apr-12-21 10:50AM	EPIX: Additional Preclinical Data Shows EPI-7386 Inhibits AR-Driven Transcription Zacks Small Cap Research
Apr-10-21 08:30AM	ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research (AACR) Annual Meeting PR Newswire
08:30AM	ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research (AACR) Annual Meeting CNW Group
Mar-26-21 04:05PM	ESSA Announces Change to its Board of Directors PR Newswire
04:05PM	ESSA Announces Change to its Board of Directors CNW Group
Mar-04-21 11:32AM	ESSA Pharma Announces Exercise of Option in Connection with Recently Completed $130 Million Financing PR Newswire
11:32AM	ESSA Pharma Announces Exercise of Option in Connection with Recently Completed $130 Million Financing CNW Group
Mar-02-21 08:00AM	LAWSUIT FILED: Ebix, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLP ACCESSWIRE
Feb-25-21 06:33PM	ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders PR Newswire
04:30PM	ESSA Pharma to Present at Upcoming March Investor Conferences PR Newswire
04:30PM	ESSA Pharma to Present at Upcoming March Investor Conferences CNW Group
07:00AM	ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer CNW Group
Feb-22-21 11:48AM	ESSA Pharma Announces Closing of $130 Million Public Offering of Common Stock PR Newswire
11:48AM	ESSA Pharma Announces Closing of $130 Million Public Offering of Common Stock CNW Group
Feb-17-21 10:47PM	ESSA Pharma Announces Pricing of Public Offering of Common Shares PR Newswire +9.31%
Feb-16-21 04:01PM	ESSA Pharma Announces Proposed Public Offering of Common Shares PR Newswire -11.92%
08:30AM	Premier Gold Reminds Securityholders of Special Meeting on February 23, 2021 and Provides Update to certain Special Meeting Business relating to SpinCo Financing CNW Group
Feb-12-21 04:40AM	EPIX: Encouraging Initial Clinical Data for EPI-7386 Zacks Small Cap Research
Feb-11-21 10:38AM	ESSA Pharma's Interim EPI-7386 Data Shows Continuous Antigen Decline In Early-Stage Prostate Cancer Study Benzinga +47.91%
08:02AM	ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium PR Newswire
08:02AM	ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium CNW Group
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2020 PR Newswire
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2020 CNW Group
Feb-05-21 04:53PM	Statement by the Prime Minister on the death of Christopher Plummer CNW Group
Jan-13-21 07:00AM	ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer PR Newswire +11.62%
07:00AM	ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer CNW Group
Jan-08-21 02:50PM	Media Advisory - Aviation Expert Lawyer Rod Winsor Available to Answer Compensation Questions for Families of Ukraine International Airline Victims CNW Group -6.09%
Dec-17-20 06:27AM	EPIX: Clinical Data for EPI-7386 in 2021 Zacks Small Cap Research
Dec-15-20 07:50PM	Is EPIX A Good Stock To Buy Now? Insider Monkey +7.21%
05:01PM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020 PR Newswire
05:01PM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020 CNW Group
Dec-08-20 09:14AM	IIROC Trade Resumption - BETR CNW Group
Nov-25-20 07:00AM	ESSA Pharma to Participate at Evercore ISI 3rd Annual HealthCONx Conference PR Newswire
Nov-13-20 12:58PM	IIROC Trading Halt - Enter Symbol(s) Here CNW Group
Nov-10-20 07:00AM	ESSA Pharma to Participate in Upcoming Investor Conferences PR Newswire
Oct-26-20 05:01PM	ESSA Pharma Inc. Announces Delisting from the TSX-V PR Newswire
Oct-24-20 07:18PM	ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd EORTC-NCI-AACR Symposium PR Newswire
Oct-19-20 07:00AM	ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia PR Newswire
07:00AM	ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia CNW Group
Sep-21-20 07:00AM	ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech Summit PR Newswire
07:00AM	ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech Summit CNW Group
Sep-17-20 05:05PM	ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020 PR Newswire
Sep-14-20 07:00AM	ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resistant Prostate Cancer PR Newswire
Sep-10-20 07:00AM	ESSA Pharma to Participate in Multiple Upcoming Investor Conferences PR Newswire
Aug-12-20 09:22AM	EPIX: $45 Million Financing Includes Investment from Pfizer; Dosing Begins in Phase 1 Trial of EPI-7386 Zacks Small Cap Research
Aug-07-20 06:16AM	Franklin Berger Is The Independent Director of ESSA Pharma Inc. (CVE:EPI) And They Just Picked Up 18% More Shares Simply Wall St.
Aug-06-20 08:00PM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020 PR Newswire
Jul-31-20 10:16AM	ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000 PR Newswire
Jul-28-20 09:18PM	ESSA Pharma Announces Pricing of Public Offering of Common Shares PR Newswire
04:01PM	ESSA Pharma Announces Proposed Public Offering of Common Shares PR Newswire
Jul-17-20 09:37AM	Have Insiders Been Buying ESSA Pharma Inc. (CVE:EPI) Shares? Simply Wall St.
Jul-15-20 07:00AM	ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer CNW Group +8.15%

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIOTECH GROWTH N V	10% Owner	Apr 27	Sale	5.85	25,100	146,925	4,990,714	Apr 28 12:28 PM
BIOTECH GROWTH N V	10% Owner	Aug 18	Buy	8.88	250,000	2,218,800	5,015,814	Aug 20 12:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience